[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643087":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":33,"responsibleParty":50,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":11,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":78,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"WGA-800CW","EXPERIMENTAL",null,[13],"Drug: WGA-800CW",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","Lectin-based fluorescent tracer",[9],[20],{"name":21,"affiliation":5,"role":22},"W.B. Nagengast, Dr, MD","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Jonathan Shaheen, PharmD","CONTACT","+31621927538","j.shaheen@umcg.nl",{"name":30,"role":26,"phone":31,"phoneExt":11,"email":32},"Chair\u002FHead of the Department of Gastroenterology and Hepatolog","+31503616161","w.b.nagengast@umcg.nl",[34],{"facility":5,"status":11,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Groningen","Provincie Groningen","9713 GZ","Netherlands","NL",{"type":41,"coordinates":42},"Point",[43,44],6.56667,53.21917,{"lat":44,"lon":43},[47,49],{"name":48,"role":26,"phone":31,"phoneExt":11,"email":32},"Wouter B Nagengast, PharmD, MD, PhD",{"name":48,"role":22,"phone":11,"phoneExt":11,"email":11},{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100643087",false,"NCT07643727","Development of Fluorescent Lectin Tracers With Dedicated Technology for in Vivo Detection of Esophageal Dysplasia in Barrett Patients","Glycan Near-Infrared Imaging Using Fluorescently Labeled Wheat Germ Agglutinin (WGA): Evaluation of Safety and Feasibility in a Prospective Pilot Study","GRAIN","Inclusion Criteria:\n\n* Patients with confirmed Barrett's esophagus, esophageal dysplasia, or superficial esophageal ade-nocarcinoma.\n* Patients scheduled for gastroscopy procedure within the UMCG.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Known allergy to wheat.\n* Celiac disease.\n* Dermatitis herpetiformis.\n* Pregnancy or breastfeeding.","ALL","18 Years",{"count":62,"type":63},49,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","The goal of this clinical trial is to evaluate the feasibility of WGA-800CW with dedicated imaging systems for detection of invisible esophageal dysplasia in patients with Barrett's esophagus.\n\nThe main questions it aims to answer are:\n\n* What is the optimal dose of WGA-800CW that maximizes the tumor-to-background ratio and enables clear visualization of the tumor?\n* Can fluorescence endoscopy with WGA-800CW in combination with qFME detect dysplastic esophageal lesions?\n\nIn this non-randomized, non-blinded, prospective, feasibility intervention study, 49 participants with Barrett's esophagus will be included. Patients will undergo the combined procedure (qFME and\u002For OCT-NIRF and HD-WLE). WGA-800CW will be topically administered via a spray catheter during gastroscopy procedures and fluorescent signal will be assessed with qFME and\u002For OCT-NIRF.",[69,70],"Barrett's Esophagus With or Without Dysplasia","Barrett Esophagus Adenocarcinoma",[72,73,74,75,76,77],"Glycan","Oncology","Fluorescent tracers","qFME","First-in-human","Lectin","NOT_YET_RECRUITING","2026-06-08",{"date":81,"type":82},"2026-06-11","ACTUAL",{"date":84,"type":63},"2026-06-01",{"date":86,"type":63},"2028-10-31",{"name":5,"class":6},1]